Cosmos Health's CMO Pipeline Hits $20M Implied Revenue at 90%+ Margins
COSM has more than doubled off its 52-week low of $0.162.
Summary
Cosmos Health's contract manufacturing arm, Cana Laboratories, now has a pipeline of over 32.7 million units, implying $20M in revenue and $18M in gross profit at margins above 90%. The pipeline has tripled since the start of 2026 and added 7.7 million units in September alone. Management frames this as a high-margin, recurring revenue stream that supports its 2029 targets of $200.6M revenue and $71.2M gross profit. The company is investing further to expand capacity toward a $10M annual gross profit goal. This follows a period of heavy dilution and going-concern warnings, making the CMO growth a notable positive offset.
At the time of this announcement, COSM was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.4M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.